NCT07243782

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 76 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 6 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea

Detailed description

This post-marketing study is a multicenter, single-arm, prospective, observational study. Cosentyx is prescribed within the scope of the approved indications for hidradenitis suppurativa, pediatric plaque psoriasis, enthesitis-related arthritis and juvenile psoriatic arthritis in the juvenile idiopathic arthritis category. The decision to treat patients with the drug will be made within current clinical practice and will be clearly distinguished from the decision to include patients in this investigation. No additional diagnostics or monitoring will be performed for this study beyond what is typically performed in clinical practice.

Conditions

• Hidradenitis Suppurativa
• Pediatric Plaque Psoriasis
• Juvenile Idiopathic Arthritis

Interventions

Type	Name	Description
DRUG	Secukinumab	This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

Timeline

• Start date: 2025-12-22
• Primary completion: 2027-06-15
• Completion: 2027-06-15
• First posted: 2025-11-24
• Last updated: 2026-03-05

Locations

1 site across 1 country: South Korea